key: cord-0767901-im215wk4
authors: Chan Ng, Pauline Poh Lin; Kang, Alicia Yi Hui; Shen, Liang; Wong, Lydia Su‐Yin; Tham, Elizabeth Huiwen
title: Improved treatment adherence and allergic disease control during a COVID‐19 pandemic lockdown
date: 2021-11-08
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13688
sha: 8068a6d36fcc171b103a74f3b164e0aabaa0a266
doc_id: 767901
cord_uid: im215wk4

Modern hectic lifestyles have created challenges for parents of allergic children, as treatment adherence and optimal disease control are closely tied to adequate caregiver supervision. Environmental allergens exposure in schools and outdoor environments are also difficult to control but impacts disease outcomes.1 Improvements in disease symptoms are often reported during school vacations,2 when children have more time at home under a caregiver's supervision. This study aimed to evaluate the impact of an 8-week (April to June 2020) COVID-19-induced nation-wide lockdown in Singapore on allergic disease control in children. Universal masking and movement restrictions (closure of schools, workplaces, retail and entertainment facilities) were implemented. This presented a unique opportunity to evaluate the impact of increased caregiver supervision, school closures, reduction of outdoor exposures and increased indoor time on allergic diseases control.

To the Editor, Modern hectic lifestyles have created challenges for parents of allergic children, as treatment adherence and optimal disease control are closely tied to adequate caregiver supervision. Environmental allergen exposures in schools and outdoor environments are also difficult to control but impacts disease outcomes. 1 An anonymous self-administered questionnaire, hosted on a secure online portal (FormSG), was disseminated to the general public through several media platforms in the one month after nationwide lockdown measures were lifted. Parents of 0-to 18-year-old children, or adolescents themselves, with allergic disorders (eczema, asthma and allergic rhinitis (AR)) were invited to complete the questionnaire anonymously. Survey completion im- A total of 41.7% of subjects with eczema reported symptomatic improvement ( Figure 1A ) and improved treatment adherence during the lockdown [median scores 7 (IQR: 5-8) and 8 (IQR: [7] [8] [9] before and during lockdown, respectively; p < .001]. This was significantly associated with a better overall perception of disease control (p < .001) and improved POEM scores: 9 (IQR: 3-13) to 6 (IQR: 3-10) (p = .001) ( Figure 1B ). Significant improvement in itch (p = .005), bleeding (p = .002), cracked skin (p = .017) and flaky skin (p = .03) was noted, but frequency of topical steroid use was not significantly reduced (p = .217) (Table S2) .

Subjects who reported perceived improvement in eczema control had a significantly higher POEM score before lockdown (median 13, IQR 7-18) compared with those who reported worsening (median 5, IQR [1] [2] [3] [4] [5] [6] [7] [8] or no change in overall eczema control (median 8, IQR 3-11) (p < .001) ( Table 1) .

Reduced exposure to triggers such as heat/sweat and physical activity (93.8%) and more time for skin care treatment (72.9%) was the most commonly cited reasons for improvement, while increased exposure to indoor triggers such as dust and heat/sweat was the most commonly cited reasons for deterioration ( Figure 2 ).

Asthmatic patients reported an overall significant improvement in perceived treatment adherence during the lockdown [median scores 9 (IQR: 8-10) and 10 (IQR: 9-10), respectively; p = .011] ( Figure S1 ) but no improvement in overall asthma control (p = .12) or ACT scores (p = .063) ( Figure 1B ). Patients with poorer asthma control before lockdown were more likely to benefit from lockdown and baseline median ACT score was 17 (IQR: 15-21) in those who improved, compared to subjects without improvement (median 24) (p = .001) ( Table 1) . Reduced exposure to infections, better sleep, more time for treatment administration, better diet and more time to seek medical attention were the main reasons for asthma improvement, while deterioration was solely attributed to increase indoor dust exposure.

There was no difference in overall median treatment adherence scores in subjects with AR (p = .201), but better adherence was associated with improved overall perception of disease control Table 1 ). All subjects reported reduced indoor dust exposure, better treatment adherence, improved diet and sleep patterns as main reasons for improved AR control. Symptom deterioration was attributed to increased indoor dust exposure, avoidance of medical consultation and lack of caregiver supervision due to remote working demands. Lack of access to medical care was not cited as a reason for poor disease control in any of the allergic disorders.

The COVID-19 lockdown had an unexpected positive impact on treatment adherence and disease symptoms in children with eczema and asthma. Eczema treatment regimens are often complex and time-consuming, 6 and non-adherence to treatment is a major reason for treatment failure. 7 The mandatory home confinement serendipitously afforded flexibility of time and increased caregiver supervision, which likely translated to improved treatment adherence and better eczema control, particularly in those with moderately severe eczema (POEM score 8-16 3 ). Reduction of outdoor heat and UVR exposure, humidity, perspiration and exercise, which are known eczema triggers, likely contributed to this improvement as well. While there was no significant reduction in frequency of topical steroid use, this is likely due to enhanced treatment compliance during the study timeframe, but data on long-term steroid requirement were not able to be captured due to the short observation period.

Poorly controlled asthmatics appear to benefit more from reduced exposure to viral respiratory infections, attributable to social distancing, enhanced mask wearing and hand hygiene practices during this lockdown period. Other studies have also observed a F I G U R E 1 Control of allergic disease before and during lockdown. A shows the breakdown of perceived overall changes in allergic disease control before and during the lockdown period by individual allergic disorders. Data are presented by percentages of the total number of individuals with a particular allergic disorder. B show comparisons of the validated symptom scores: Patient-Oriented Eczema Measure (POEM) scores for eczema, Asthma Control Test (ACT) scores for asthma and Total Nasal Symptom Score (TNSS) for allergic rhinitis before and during the lockdown period. POEM scores range from 0 to 28, with a higher score indicating poorer disease control. ACT scores range from 5 to 25 with higher scores indicating better disease control. TNSS scores range from 0 to 12, with higher scores indicating poorer disease control reduction in viral infections, Emergency Department visits and admissions for wheezing and asthma exacerbations during the COVID-19 pandemic. 8, 9 Reduced healthcare access or medication supply disruptions were not reasons for worsening disease control. Possible reasons may include enhanced telemedicine practices, which is particularly TA B L E 1 Patient rated scores before and during lockdown and overall perceived disease status during lockdown Abbreviations: AD, atopic dermatitis; ACT, asthma control test; POEM, patient-oriented eczema measure; TNSS, total nasal symptom score.

*Analysed by Kruskal-Wallis Test.

Factors implicated in Eczema (AD) control. More time for administration of skin treatment (n = 35) and reduced exposure to triggers (n = 45) (4A) such as physical activity (n = 22) and heat/sweating (n = 35) (4B) were the main reasons for improved eczema control during the lockdown period. Increased exposure to indoor triggers (4C) such as house dust mites (HDM) (n = 16) and heat/sweat (n = 15) (4D) were the main reasons for poor eczema control. Other reported reasons included increased hand washing/hand sanitizers, prolonged exposure to air-conditioning leading to excessive skin dryness and increased stress from being confined indoors and excessive drooling suitable for stable allergic diseases, 10 and home delivery of medications in the local setting, which may help to ensure continued access to medical care.

This was a small pilot cross-sectional study without a longitu- 

The authors have no conflicts of interest to declare. 

The management of the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school

Seasonality of medical contacts in school-aged children with asthma: association with school holidays

The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective

Development and crosssectional validation of the Childhood Asthma Control Test

Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper

Managing childhood eczema: qualitative study exploring carers' experiences of barriers and facilitators to treatment adherence

Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis

Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan

Pediatric asthma health care utilization, viral testing, and air pollution changes during the COVID-19 pandemic

Work group report: COVID-19: unmasking telemedicine